{"id":"etiprednol-dicloacetate","rwe":[{"pmid":"28980320","year":"2017","title":"Potent analogues of etiprednol dicloacetate, a second generation of soft corticosteroids.","finding":"","journal":"The Journal of pharmacy and pharmacology","studyType":"Clinical Study"},{"pmid":"28017774","year":"2017","title":"Identification of esterase involved in the metabolism of two corticosteroid soft drugs.","finding":"","journal":"Biochemical pharmacology","studyType":"Clinical Study"},{"pmid":"17020532","year":"2006","title":"Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids.","finding":"","journal":"Current pharmaceutical design","studyType":"Clinical Study"},{"pmid":"16594634","year":"2005","title":"Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems.","finding":"","journal":"The AAPS journal","studyType":"Clinical Study"},{"pmid":"15212312","year":"2004","title":"Anti-inflammatory effect and soft properties of etiprednol dicloacetate (BNP-166), a new, anti-asthmatic steroid.","finding":"","journal":"Die Pharmazie","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"etiprednol dichloroacetate","offLabel":[],"synonyms":["BNP166","etiprednol dichloroacetate","etiprednol dicloacetate"],"timeline":[],"approvals":[],"brandName":"Etiprednol Dichloroacetate","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your body's cells have locks on them, and Etiprednol Dichloroacetate is a key that fits into those locks. When it binds to the locks, it can either open or close the cell's activity, depending on the specific lock and key interaction. However, the exact way it interacts with these locks is still a mystery.","oneSentence":"Etiprednol Dichloroacetate is a small molecule that works by interacting with specific biological pathways, but the exact mechanism is unknown.","technicalDetail":"Etiprednol Dichloroacetate's mechanism of action is likely to involve modulation of specific protein targets, but the precise molecular details are unknown."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3209","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ETIPREDNOL%20DICLOACETATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ETIPREDNOL DICLOACETATE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:09:35.603251","biosimilars":[],"competitors":[],"genericName":"etiprednol dicloacetate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00035503","phase":"PHASE2","title":"Multicenter Trial For Patients With Acute Crohn's Disease","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2002-01-31","conditions":["Crohn's Disease"],"enrollment":0,"completionDate":"2004-01-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"332VLD554F","CHEBI":"CHEBI:135783","INN_ID":"8329","UMLSCUI":"C1317969","ChEMBL_ID":"CHEMBL2107614","KEGG_DRUG":"D04100","DRUGBANK_ID":"DB05442","PUBCHEM_CID":"9935073","SECONDARY_CAS_RN":"182069-13-2","MESH_SUPPLEMENTAL_RECORD_UI":"C450000"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":9,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2017 Dec","pmid":"28980320","title":"Potent analogues of etiprednol dicloacetate, a second generation of soft corticosteroids.","journal":"The Journal of pharmacy and pharmacology"},{"date":"2017 Mar 1","pmid":"28017774","title":"Identification of esterase involved in the metabolism of two corticosteroid soft drugs.","journal":"Biochemical pharmacology"},{"date":"2006","pmid":"17020532","title":"Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids.","journal":"Current pharmaceutical design"},{"date":"2005 Dec 7","pmid":"16594634","title":"Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems.","journal":"The AAPS journal"},{"date":"2004 May","pmid":"15212312","title":"Anti-inflammatory effect and soft properties of etiprednol dicloacetate (BNP-166), a new, anti-asthmatic steroid.","journal":"Die Pharmazie"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etiprednol dichloroacetate is a small molecule with the synonyms BNP-166, dicloacetate d'etiprednol, and others.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}